155 related articles for article (PubMed ID: 33434085)
1. PI3K inhibition as a novel therapeutic strategy for neoadjuvant chemoradiotherapy resistant oesophageal adenocarcinoma.
Edge SD; Renard I; Pyne E; Li C; Moody H; Roy R; Beavis AW; Archibald SJ; Cawthorne CJ; Maher SG; Pires IM
Br J Radiol; 2021 Mar; 94(1119):20201191. PubMed ID: 33434085
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.
Bibby BA; Reynolds JV; Maher SG
PLoS One; 2015; 10(7):e0134180. PubMed ID: 26221725
[TBL] [Abstract][Full Text] [Related]
3. Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer.
Koyama FC; Lopes Ramos CM; Ledesma F; Alves VAF; Fernandes JM; Vailati BB; São Julião GP; Habr-Gama A; Gama-Rodrigues J; Perez RO; Camargo AA
Br J Surg; 2018 Jan; 105(2):e192-e203. PubMed ID: 29341150
[TBL] [Abstract][Full Text] [Related]
4. Visceral Adipose Tissue Modulates Radiosensitivity in Oesophageal Adenocarcinoma.
Mongan AM; Lynam-Lennon N; Doyle SL; Casey R; Carr E; Cannon A; Conroy MJ; Pidgeon GP; Brennan L; Lysaght J; Reynolds JV; O'Sullivan J
Int J Med Sci; 2019; 16(4):519-528. PubMed ID: 31171903
[TBL] [Abstract][Full Text] [Related]
5. Silencing microRNA-330-5p increases MMP1 expression and promotes an invasive phenotype in oesophageal adenocarcinoma.
Bibby BAS; Miranda CS; Reynolds JV; Cawthorne CJ; Maher SG
BMC Cancer; 2019 Aug; 19(1):784. PubMed ID: 31391080
[TBL] [Abstract][Full Text] [Related]
6. MiRNA Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neoadjuvant Chemoradiotherapy.
Wen J; Luo K; Liu H; Liu S; Lin G; Hu Y; Zhang X; Wang G; Chen Y; Chen Z; Li Y; Lin T; Xie X; Liu M; Wang H; Yang H; Fu J
Ann Surg; 2016 May; 263(5):942-8. PubMed ID: 26445467
[TBL] [Abstract][Full Text] [Related]
7. Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.
Donlon NE; Davern M; O'Connell F; Sheppard A; Heeran A; Bhardwaj A; Butler C; Narayanasamy R; Donohoe C; Phelan JJ; Lynam-Lennon N; Dunne MR; Maher S; O'Sullivan J; Reynolds JV; Lysaght J
World J Gastroenterol; 2022 Jun; 28(21):2302-2319. PubMed ID: 35800186
[TBL] [Abstract][Full Text] [Related]
8. High CD8
Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA Profiling in Oesophageal Adenocarcinoma Cell Lines and Patient Serum Samples Reveals a Role for miR-451a in Radiation Resistance.
Butz F; Eichelmann AK; Mayne GC; Wang T; Bastian I; Chiam K; Marri S; Sykes PJ; Wijnhoven BP; Toxopeus E; Michael MZ; Karapetis CS; Hummel R; Watson DI; Hussey DJ
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255413
[TBL] [Abstract][Full Text] [Related]
10. Altered mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal adenocarcinoma.
Lynam-Lennon N; Maher SG; Maguire A; Phelan J; Muldoon C; Reynolds JV; O'Sullivan J
PLoS One; 2014; 9(6):e100738. PubMed ID: 24968221
[TBL] [Abstract][Full Text] [Related]
11. Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
Machackova T; Trachtova K; Prochazka V; Grolich T; Farkasova M; Fiala L; Sefr R; Kiss I; Skrovina M; Dosoudil M; Berindan-Neagoe I; Svoboda M; Slaby O; Kala Z
Cancer Genomics Proteomics; 2020; 17(3):249-257. PubMed ID: 32345666
[TBL] [Abstract][Full Text] [Related]
12. Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma.
Lynam-Lennon N; Bibby BA; Mongan AM; Marignol L; Paxton CN; Geiersbach K; Bronner MP; O'Sullivan J; Reynolds J; Maher SG
Mol Med; 2016 May; 22():388-97. PubMed ID: 27254108
[TBL] [Abstract][Full Text] [Related]
13. GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma.
Gotovac JR; Liu DS; Yates MJ; Milne JV; Macpherson AA; Simpson KJ; Eslick GD; Mitchell C; Duong CP; Phillips WA; Clemons NJ
J Pathol; 2020 Nov; 252(3):317-329. PubMed ID: 32737994
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoradiotherapy improves histological results compared with perioperative chemotherapy in locally advanced esophageal adenocarcinoma.
Luc G; Vendrely V; Terrebonne E; Chiche L; Collet D
Ann Surg Oncol; 2015 Feb; 22(2):604-9. PubMed ID: 25169119
[TBL] [Abstract][Full Text] [Related]
15. Proteomic signatures of radioresistance: Alteration of inflammation, angiogenesis and metabolism-related factors in radioresistant oesophageal adenocarcinoma.
Marcone S; Buckley A; Ryan CJ; McCabe M; Lynam-Lennon N; Matallanas D; O Sullivan J; Kennedy S
Cancer Treat Res Commun; 2021; 27():100376. PubMed ID: 33882379
[TBL] [Abstract][Full Text] [Related]
16. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation.
Maher SG; McDowell DT; Collins BC; Muldoon C; Gallagher WM; Reynolds JV
Ann Surg; 2011 Nov; 254(5):809-16; discussion 816-7. PubMed ID: 22005152
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P
BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748
[TBL] [Abstract][Full Text] [Related]
18. Radiation field size and dose determine oncologic outcome in esophageal cancer.
Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
[TBL] [Abstract][Full Text] [Related]
19. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Zanoni A; Verlato G; Giacopuzzi S; Weindelmayer J; Casella F; Pasini F; Zhao E; de Manzoni G
Ann Surg Oncol; 2013 Jun; 20(6):1993-9. PubMed ID: 23274533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
